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Summary
Background: Inhaled corticosteroids (ICS) are the most effective anti-inflammatory
agents available for the treatment of asthma but they produce only modest effects
on airway inflammation and non-specific bronchial hyperresponsiveness (BHR).
However, little is known about the possibility that treatment with ICS might cause
additional protection on BHR to inhaled tachykinins such as neurokinin A (NKA).
Objective: Therefore, we compared the effects of beclomethasone dipropionateee front matter & 2005
med.2005.09.038
ing author. Tel.: +39 095
ess: polosa@unict.it (R.(BDP) on the degree of BHR to inhaled histamine and NKA in a double-blind,
controlled, cross-over study of asthmatic patients.
Methods: Patients attended the laboratory before and after each 6 weeks
treatment period to undertake concentration–response studies with histamine and
NKA. Bronchial responsiveness to both funs was expressed as the provocative
concentration producing a 20% decrease in FEV1 from baseline (PC20).
Results: BDP therapy attenuated the constrictor response to both agonists to a
similar degree, their geometric mean (range) PC20 values increasing from 0.47
(0.21–1.41)mg/ml to 2.43 (0.51–4.50)mg/ml (Po0.01, post-salb vs. post-BDP
treatment) and from 101.7 (27.3–356.1) mg/ml to 666.7 (151.5–1000) mg/ml
(Po0.01, post-salb vs. post-BDP treatment) for histamine and NKA, respectively.
Conclusion: Airway responsiveness to histamine and NKA is reduced by BDP to the
same extent. As a result of these findings, provocation with NKA is unlikely to
provide additional useful information in the assessment of airway inflammation in
asthma.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
7594506; fax: +39 09330707.
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airways characterized by bronchial hyperrespon-
siveness (BHR), which can be defined as an increase
in the degree of airway narrowing in response to
stimuli that have little or no effect in normal
subjects.1 Although the precise mechanisms under-
lying BHR remain poorly understood, it is now
widely accepted that distinctive inflammatory
processes in the airway wall have a major role in
its development.2,3 There is also evidence for a
definite association between degree of BHR and
severity of asthma, indicating that treatment of
asthma should also aim at reducing the degree of
BHR.3–5
It is well established that inhaled corticosteroids
(ICS) are effective at reducing BHR to a wide range
of stimuli and that the magnitude of this reduction
is usually related to the dosage and length of
treatment (reviewed in 3). In particular, monitoring
airway responsiveness with indirect stimuli appears
to have the selective ability to probe changes in
airway inflammation and it has been shown to be
very useful when evaluating the effectiveness of
ICS.6,7 However, the effect of ICS on airway
responsiveness to inhaled tachykinins has not been
investigated in depth. The tachykinins, substance P
(SP) and neurokinin A (NKA), are sensory neuropep-
tides exhibiting a range of features that may be
relevant to the pathophysiology of asthma includ-
ing contraction of airways smooth muscle, in-
creased vascular permeability, and mucus
secretion.8–10. When administered by inhalation
NKA provokes dose-related bronchoconstriction in
asthmatic subjects but its mode of action is not
well understood.11,12. The bronchoconstrictor ef-
fect of NKA in asthma is largely inhibited by prior
treatment with nedocromil sodium, 11,12 suggesting
that this response may be evoked indirectly rather
than through direct stimulation of airway smooth
muscle. This indirect bronchoconstrictor effect of
NKA appears to be mediated by activation of a
specific tachykinin NK2 receptor.13
As for many other neuropeptides mediator of
asthma, its biological function is terminated by the
combined action of a variety of peptidases such as
neutral endopeptidase (NEP), a membrane-bound
enzyme that modulates NKA’s physiological and
pathophysiological responses by degrading it to
inactive metabolites.14 In the human respiratory
tract, NEP has been detected in bronchial epithelial
cells, sub-mucosal glands, bronchial smooth muscle
and vascular endothelium,15 sites known to express
receptors for NKA. In support of the view that
enzymatic modulation of NKA responses is alsopre-treatment with the NEP-inhibitor phosphora-
midon enhances NKA-induced bronchoconstriction
in asthmatic subjects.16,17
NEP activity in human airways could be up
regulated by corticosteroids. Borson et al.18 have
shown that ICS increase the level of NEP expression
in human airway epithelial cells. We hypothesized
that, if NEP activity is also enhanced by corticos-
teroids in asthmatic airways in vivo, then the
airway response to inhaled NKA could be further
reduced upon treatment with ICS when compared
with agonists, such as histamine, which are known
not to be metabolized by NEP.
To test this hypothesis, we performed a 6 wks,
double-blind, controlled, cross-over study compar-
ing the effects of inhaled beclomethasone dipro-
pionate (BDP) on airways responsiveness to NKA and
histamine in a group of steroid naı¨ve asthmatic
subjects.Methods
Subjects studied
Fifteen patients were enrolled in the study and
randomized to receive BDP or salbutamol, but 4
subjects were withdrawn from the trial because of
non-compliance with BDP usage and excluded from
further analysis. The remaining 11 subjects (7M, 4F)
were non-smokers, with a mean (7SEM) age of 31.1
(72.7) and with mild-moderate asthma (Table 1).
All were atopic, as defined by a positive skin prick-
test reaction (43mm wheal response) to one or
more of 6 common aeroallergens (Dermatopha-
goides pteronyssinus, Dermatophagoides farinae,
Parietaria pollen, mixed grass pollens, cat fur, dog
hair). Inclusion criteria comprised stable asthma
(having had no exacerbation or respiratory tract
infection in the previous 2 months), baseline forced
expiratory volume in 1 s (FEV1) of greater than 65%
of their predicted values, and documented BHR to
inhaled NKA. Patients had never used ICS before or
had stopped their use at least 2 months before
entry into the study. Throughout the study, only
short acting inhaled beta2-adrenoreceptor agonists
were allowed for relief of symptoms but were
withheld for at least 8 h prior to each visit to the
laboratory. Antihistamines and/or cromones were
not taken throughout the investigation. The local
hospital’s ethics committee approved the study and
written informed consent was obtained for each
patient.
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Table 1 Details of patients’ chracteristics at screening.
Patient no. Sex Age (yr) Baseline FEV1
(%predicted)
Atopy PC20 histamine
(mg/ml)
PC20 NKA (mg/
ml)
1 M 30 67 G-P 1.56 100.8
2 M 38 77 D 1.07 209.7
3 M 54 66 P 0.52 287.0
4 F 28 80 D-P 0.44 533.1
5 F 33 71 P 0.29 189.9
6 M 23 73 P 0.66 175.7
7 M 27 78 D 0.7 444.5
8 M 28 81 D-G 0.3 83.0
9 F 24 72 P 0.6 122.9
10 F 29 81 D-G-P 0.28 30.8
11 M 28 70 P 0.64 94.2
Mean (7SEM) 31.1 (2.7) 74.2 (1.8)
G. mean (range) 0.56
(0.28–1.56)
156.9
(30.8–533.1)
FEV1 ¼ forced expiratory volume in 1 s.
PC20 ¼ provocation concentration producing a 20% fall from baseline FEV1.
Positive immediate skin test to one or more allergens including: G ¼ grass pollen, P ¼ Parietaria pollen, and
D ¼ Dermatophagoides.
G. Prosperini et al.1008Study design
All visits to the laboratory took place at the same
time of the day and outside the pollen season. As it
was felt ethically unacceptable to leave such
patients on placebo treatment alone for such a
long period of time and considering that short
acting inhaled beta2-adrenoreceptor agonists do
not modify non-specific BHR,19–22 it was decided to
use a short acting bronchodilators (salbutamol) as
an alternative.
As our working hypothesis was to test if BHR to
inhaled NKA could be further reduced (compared to
histamine) due to enhanced NEP activity by ICS in
asthma, we wanted to achieve the highest level of
NEP induction by using very high doses of BDP
(2000 mg/daily—that is BDP 250 mg two puffs
q.i.d.). In order to match the BDP administration
regimen, we opted to administer salbutamol 100 mg
in the same fashion (two puffs q.i.d.; this gives a
total of 800 mg/daily).
Patients were therefore randomised using
computer-generated numbers into a double-
blind, controlled, crossover study with either
BDP 250 mg two puffs q.i.d. or salbutamol 100 mg
two puffs q.i.d. using a standard metered-dose
inhaler attached to a spacer device for 6 wks
separated by a washout period of at least 3–4 wks.
Patients attended the laboratory before and
after each treatment period to undertake concen-
tration–response studies with inhaled histamine
and NKA. Each patient was challenged withhistamine first followed by NKA challenge at least
2 h later when FEV1 had spontaneously returned to
within 5% of the baseline FEV1 level. The order of
inhalation challenges was identical for all patients
throughout the study. Treatment was commenced
immediately after completion of NKA challenge and
continued up for 6 wks. Treatment was discontin-
ued at least 12 h prior to bronchial challenge.
Study inhalers were weighed throughout the
study to assess compliance. Patients were consid-
ered compliant if, in their BDP arm of the study, the
total number of actuations fired from the inhalers
was at least 60% of the number of actuations
prescribed.Bronchoprovocation testing with inhaled
histamine and NKA
BHR was evaluated by means of histamine and NKA
bronchial challenge, as described previously.23 In
brief, histamine (Sigma Chemical Co, St. Louis, MO,
USA) and NKA (Peninsula Laboratories Ltd) were
made up in 0.9% sodium chloride (1% albumin
solution) to produce a range of increasing doubling
concentrations of 0.03–16.00mg/ml and 3.9–500mg/
ml, respectively. The aqueous solutions were admi-
nistered as aerosols generated from a starting
volume of 3ml in a disposable Inspiron Mini-nebuliser
(C.R. Bard International, Sunderland, UK) driven by
compressed air at a flow rate of 8 l/min. Wearing a
nose-clip, subjects inhaled the aerosolized solutions
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inspiratory capacity via a mouthpiece. Airway calibre
was recorded as the forced respiratory volume in 1 s
(FEV1) using a dry wedge spirometer (Vitalograph,
Buckinghamshire, UK), the better of the two
consecutive measurements being used for analysis.
After 15min rest, three consecutive baseline mea-
surements of FEV1 were made at intervals of 3min
followed by inhalation of 0.9% sodium chloride
solution and further FEV1 measurements repeated
at 1 and 3min. Provided FEV1 had not fallen by410%
from baseline, increasing doubling concentrations of
agonists were administered and FEV1 measured at
intervals of 1 and 3min. The challenges were
discontinued when FEV1 had fallen 420% of the
post-saline baseline value or when the highest
concentration of agonist had been administered.
The fall in the FEV1 following each concentration of
agonist was expressed as percentage of the higher of
the two post-saline baseline FEV1 recordings. The
percentage fall in FEV1 was plotted against the
cumulative concentration of agonist on a logarithmic
scale and the provocative concentration required to
produce a 20% decrease in FEV1 from the post-saline
baseline value (PC20) was determined by linear
interpolation.Data analyses
Results are expressed as mean (7SEM) unless
otherwise stated and p values of o0.05 were
accepted as the minimum level of statistical
significance. Baseline values of FEV1 before and
after study treatments were compared between
and within study days by two-factor analysis of
variance (ANOVA).
PC20 histamine and NKA values were log-trans-
formed and compared by means of two-factor
ANOVA. After treatment with BDP a 20% fall in
FEV1 was not obtained in seven subjects
1,3–7,11 at
the highest concentration of NKA administered, and
therefore a minimal estimate was obtained by
calculating the cumulative PC20, on the next
doubling concentration beyond the highest admi-
nistered. Because of these censored data the
results were also compared for significance with
Wilcoxon’s signed rank test.
The protective effect of BDP against broncho-
provocation with each agonist was calculated by
working out the difference in PC20 before and after
BDP and the control drug (salbutamol) in each
individual patient and expressed in terms of mean
(7SEM) doubling dilutions. Paired t tests were then
used to compare post-drug variations in BHR to
histamine and NKA.Results
There was no significant difference in mean (7SEM)
baseline values of FEV1 between pre-treatment
study days. As expected, treatment with BDP
caused a small but significant 6.4% increase in
mean FEV1 from baseline (P ¼ 0:032), whereas 6
wks administration of the control drug (salbutamol)
did not produce significant changes.
Baseline PC20 values for histamine and NKA were
not significantly different between pre-treatment
study days (Table 2). BDP therapy for 6 wks
significantly attenuated the constrictor response
to both agonists, their geometric mean (range) PC20
values increasing from 0.47 (0.21–1.41)mg/ml to
2.43 (0.51–4.50)mg/ml (Po0.01, post-salb vs.
post-BDP treatment) and from 101.7
(27.3–356.1) mg/ml to 666.7 (151.5–1000) mg/ml
(Po0.01, post-salb vs. post-BDP treatment) for
histamine and NKA, respectively (Table 2).
When changes in the protective effect of inhaled
BDP on provocation responses were expressed as
doubling dilutions, a mean (7SEM) protection of
2.37 (70.29) doubling doses against histamine and
of 2.71 (70.31) doubling doses against NKA were
reported (Fig. 1). These changes were not signifi-
cantly different from each other.Discussion
Six weeks’ treatment with inhaled BDP had a
significant protective effect against BHR to both
histamine and NKA. The magnitude of this effect
was similar for histamine and NKA, their dose–
response curves being displaced to the right by 2.37
and 2.71 doubling doses, respectively. In the
current study, patients with mild-moderate asthma
receiving BDP (2000 mg/daily) showed a small but
significant improvement in FEV1, confirming the
efficacy of this dose of drug.
Due to ethical restrictions, it was decided to use
salbutamol as an alternative for placebo as there is
ample evidence that regular use of short acting
beta2 agonists does not affect BHR.19–22 Indeed,
under similar experimental conditions, Tormey et
al.21 were unable to demonstrate significant differ-
ences in BHR to histamine between placebo and
salbutamol (800 mg/daily) treatment periods in
adult asthma. Likewise, Kozlik-Feldmann et al.20
demonstrated that regular salbutamol (800 mg/
daily) over a period of 3 months did not deteriorate
BHR to inhaled histamine in asthmatic children. In
addition, when four crossover studies comparing
regular short acting beta2-agonist treatment with
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Figure 1 Changes in PC20 histamine and PC20 NKA values
expressed as mean change (7SEM) in doubling dilutions
after each 6-week treatment period with salbutamol
(control period) and beclomethasone dipropionate—BDP
(study period). Salbutamol ¼ open circles; BDP ¼ closed
circles. **Po0.01 (post-salb vs. post-BDP treatment).
Table 2 Individual changes in airways hyperresponsiveness to histamine and NKA after 6 wks treatment with
BDP and salbutamol.
Patient no. PC20 histamine PC20 NKA
Pre-BDP Post-BDP Pre-salb Post-salb Pre-BDP Post-BDP Pre-salb Post-salb
1 1.06 4.5 1.56 1.41 153.3 1000.0 154.6 67.1
2 0.59 2.12 0.41 0.94 254.9 815.8 389.9 356.1
3 1.1 3.89 0.26 0.46 313.7 1000.0 242.5 268.1
4 0.4 4.04 0.37 0.8 578.1 1000.0 296.7 344.1
5 0.38 3.71 0.43 0.35 184.7 1000.0 220.2 135.9
6 0.5 2.21 0.35 0.48 114.1 1000.0 129.5 117.1
7 0.37 4.06 0.19 0.21 476.5 1000.0 41.8 85.5
8 0.35 0.89 0.2 0.21 60.7 363.3 97.8 61.0
9 0.56 2.01 0.96 0.53 106.0 257.8 120.3 48.4
10 0.19 0.51 0.12 0.22 36.8 151.5 32.8 27.3
11 1.04 3.91 1.16 0.6 114.9 1000.0 67.1 49.9
G. mean 0.52 2.43 0.40 0.47 161.4 666.7 126.6 101.7
(Range) (0.19–1.10) (0.51–4.50) (0.12–1.56) (0.21–1.41) (36.8–578.1) (151.5–1000) (32.8–389.9) (27.3–356.1)
BDP ¼ beclomethasone dipropionate; salb ¼ salbutamol.
G. Prosperini et al.1010placebo were pooled together in a recent Cochrane
review, no significant difference in change in AHR
was observed, the mean change being 0.09 dou-
bling doses (95%CI–0.18, 0.35).24 Lastly, the issue of
a potential effect of salbutamol on BHR in the
placebo group it is likely to be irrelevant in virtue
of the cross-over design of the present study.
The magnitude of the decrease in BHR to
histamine after ICS is consistent with that of
previously reported studies.25–27 However, the
results of the present study with BDP differ some-
what from those of the recent work by Van Schooret al.28 who demonstrated that inhaled fluticasone
propionate reduced BHR to NKA to a greater extent
compared to methacholine. This discrepancy could
be related to the well known superior potency of
fluticasone compared to BDP as there is abundant
evidence that all comparative studies in asthma
have shown at least a 2:1 ratio in clinical effects
(reviewed in29). In particular, the elegant study by
Bootsma et al. has demonstrated that fluticasone is
as effective as twice the dose of BDP on BHR
assessed by provocation with both direct (hista-
mine) and indirect (UNDW—‘‘fog’’ challenge) sti-
muli.25 That this might be the case is also reflected
by studies in which the effects of fluticasone and
budesonide were tested against the airways re-
sponsiveness to bradykinin (the bronchoconstrictor
effect of bradykinin is, at least in part, mediated
via release of NKA—reviewed in30); in these studies
fluticasone was effective at reducing BHR to
inhaled bradykinin31 whereas budesonide was
not.32 Thus, despite the established dogma that
ICS are the most effective anti-inflammatory agents
available for asthma, comparison of the effect
between different ICS on NKA responses may reveal
dissimilar level of protection reflecting heteroge-
neous response to different ICS. However, it must
be noted that the use and dose of BDP and the
length of BDP therapy in our study should have
minimized differences in potency between the
different drug preparations across studies. Taken
together, the above-mentioned considerations call
for rigorous trials comparing the effect of different
ICS on challenges performed in the same group of
patients.
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in results may be due to dissimilar methodology and
to distinctive patients’ characteristics. If Van
Schoor et al.28 would have compared post-pla vs.
post-fluticasone variations rather than pre vs. post-
fluticasone variations, they could have seen less
marked changes in BHR to NKA. In addition, it could
be argued that a 2-week course of fluticasone
would simply fail to elicit a maximal protective
effect against methacholine in such a short period
of time; for example, it is possible that a 4-week
course of fluticasone could have produced a
stronger protective effect against methacholine
resulting in a less pronounced relative reduction in
BHR to NKA. Conversely, given that 7 of 11 patients
failed to show a 20% fall in FEV1 at the highest dose
of NKA administered after treatment with BDP, our
conservative approach of assigning a PC20 value to
these patients means that the reduction in NKA
responsiveness is likely to be underestimated.
The working hypothesis that airway responsive-
ness to inhaled NKA could be further reduced due
to the enhanced NEP activity by ICS in asthma, it is
not supported by the results of the present
investigation and reflects the reported discrepan-
cies described by a number of in vitro studies. Some
authors have shown that ICS increase the level of
NEP expression and of enzymatic activity in human
airway epithelial cells,18,33 but others failed to
confirm these observations.34,35 In addition,
although NEP expression is significantly enhanced
in the airway epithelium of asthmatic patients on
ICS as compared with steroid naı¨ve asthmatics,36 no
differences in peptidase activities in serum or BAL
fluid were observed between fluticasone propio-
nate users and non-users in allergic asthma.37
Whatever the cause for the discrepancies ob-
served, it is apparent that NKA challenge is not
useful for monitoring changes in airway inflamma-
tion even in the hands of experienced researchers.
Moreover, this should be discussed against the
evidence of the superior sensitivity profile of other
non-invasive markers of airway inflammation (such
as AMP challenge, exhaled NO, and sputum eosino-
phils) for use in diagnosis, monitoring the disorder’s
activity, and evaluating airways response to anti-
inflammatory therapy in asthma (reviewed in7,38).Acknowledgements
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